Beta-Caryophyllene, a Cannabinoid Receptor Type 2 Selective Agonist, in Emotional and Cognitive Disorders
International Journal of Molecular Sciences · 11.03.2024 · 25 (6) · 3203
DOI: 10.3390/ijms25063203 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 11.03.2024. Verfasst von Caterina Ricardi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of Pisa, 56126 Pisa, Italy. Hauptthemen laut MEDLINE: Cannabinoid Receptor Agonists, Cognitive Dysfunction, Polycyclic Sesquiterpenes. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 136 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Mental disorders account for one of the most prevalent categories of the burden of disease worldwide, with depression expected to be the largest contributor by 2030, closely followed by anxiety. The COVID-19 pandemic possibly exacerbated these challenges, especially amongst adolescents, who experienced isolation, disrupted routines, and limited healthcare access. Notably, the pandemic has been associated with long-term neurological effects known as “long-COVID”, characterized by both cognitive and psychopathological symptoms. In general, psychiatric disorders, including those related to long-COVID, are supposed to be due to widespread inflammation leading to neuroinflammation. Recently, the endocannabinoid system (ECS) emerged as a potential target for addressing depression and anxiety pathophysiology. Specifically, natural or synthetic cannabinoids, able to selectively interact with cannabinoid type-2 receptor (CB2R), recently revealed new therapeutic potential in neuropsychiatric disorders with limited or absent psychotropic activity. Among the most promising natural CB2R ligands, the bicyclic sesquiterpene β-caryophyllene (BCP) has emerged as an excellent anti-inflammatory and antioxidant therapeutic agent. This review underscores BCP’s immunomodulatory and anti-inflammatory properties, highlighting its therapeutic potential for the management of depression and anxiety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, University of Pisa, 56126 Pisa, Italy.
- Hematology Division, Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy.
- Department of Psychiatry, University of Pisa, 56126 Pisa, Italy.
- UniCamillus, Saint Camillus International University of Health and Medical Sciences, 00151 Rome, Italy.
ORCID-Profile: Serena Barachini, Donatella Marazziti, Beatrice Polini, Grazia Chiellini
Zitieren
APA
Ricardi, C., Barachini, S., Consoli, G., Marazziti, D., Polini, B., & Chiellini, G. (2024). Beta-Caryophyllene, a Cannabinoid Receptor Type 2 Selective Agonist, in Emotional and Cognitive Disorders. International Journal of Molecular Sciences, 25(6), 3203. https://doi.org/10.3390/ijms25063203
Vancouver
Ricardi C, Barachini S, Consoli G, Marazziti D, Polini B, Chiellini G. Beta-Caryophyllene, a Cannabinoid Receptor Type 2 Selective Agonist, in Emotional and Cognitive Disorders. International Journal of Molecular Sciences. 2024;25(6):3203. doi:10.3390/ijms25063203
BibTeX
@article{Ricardi2024,
author = {Ricardi, Caterina and Barachini, Serena and Consoli, Giorgio and Marazziti, Donatella and Polini, Beatrice and Chiellini, Grazia},
title = {Beta-Caryophyllene, a Cannabinoid Receptor Type 2 Selective Agonist, in Emotional and Cognitive Disorders},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {6},
pages = {3203},
doi = {10.3390/ijms25063203}
}
EUVIMED